We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. markets closed

Cytokinetics, Incorporated (CYTK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
71.56-1.63 (-2.23%)
At close: 04:00PM EDT
71.11 -0.45 (-0.63%)
After hours: 07:49PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close73.19
Open73.76
Bid71.55 x 200
Ask71.74 x 100
Day's Range70.61 - 73.76
52 Week Range25.98 - 110.25
Volume789,376
Avg. Volume2,224,883
Market Cap7.483B
Beta (5Y Monthly)0.68
PE Ratio (TTM)N/A
EPS (TTM)-5.45
Earnings DateMay 02, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est95.06
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CYTK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cytokinetics, Incorporated
    CYTK: Raising target price to $79.00CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $79.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • MarketWatch

    This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

    GLP-1 medications will likely expand beyond their current uses for diabetes or weight loss, according to money managers at Tema

  • GlobeNewswire

    Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress

    Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional Analyses from SEQUOIA-HCM Assess Effect of Aficamten on Exercise Capacity and Dosing and Safety SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Clinical Trial presentations relating to SEQUOIA-HCM, (Safety, Efficacy, and Quantitative Understanding of Obstructi

  • GuruFocus.com

    EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)

    Cytokinetics Inc (NASDAQ:CYTK), a biopharmaceutical company focused on the discovery and development of next-generation therapeutics for muscle diseases, has reported an insider sale according to a recent SEC filing.

  • GlobeNewswire

    Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session

    Treatment with Aficamten for 48 Weeks is Associated with Improvements in Clinical Efficacy Endpoints, NYHA Class and Cardiac Biomarkers, Structure and FunctionSOUTH SAN FRANCISCO, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional 48-week data from FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), the open label extension clinical study of aficamten in patients with hypertrophic cardi

  • GlobeNewswire

    Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 29, 2024 it granted stock options to purchase an aggregate of 78,000 shares of common stock to five new employees, whose employment commenced in March 2024, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $70.11 per share, which is equal to the closing price of the Company’s common stock on Ma

  • GlobeNewswire

    Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 at 2:15 PM Eastern Time. Interested parties may access the live webcast of this fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetic

  • GlobeNewswire

    Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session

    SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 73rd Annual Scientific Session (ACC.24) taking place in Atlanta, GA from April 6, 2024 – April 8, 2024. Title: 1075-11 - Efficacy and Safety of Aficamten in the First Cohort of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Completing 1-Year Follow-Up: Findings From the FOREST-HCM StudyPresenter: Sara

  • Motley Fool

    2 Incredible Growth Stocks to Buy Right Now

    These two biotech stocks could be big winners in the years ahead.

  • InvestorPlace

    7 Biotech Stocks Ready to Ride the Sector’s Resurgence

    Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation. First, the hard data supports bullishness in biotech stocks. According to Grand View Research, the underlying global industry reached a valuation of $1.55 trillion last year. Moving forward, experts project that the sector will expand at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030. At the culmination point, the space may be worth $3.88 trillion. Second, a sector r

  • Insider Monkey

    30 Biggest Biotechnology Companies in the World

    In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]